← Leaderboards
Liangfang Zhang
University Of California, San Diego
$5,562,722
Attributed
$10,071,774
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,071,774 · 8
By mechanism
R01$7,978,796 · 5
R33$1,352,019 · 1
R21$740,959 · 2
Top collaborators
- Lars Eckmann6 shared
- Shulin Li5 shared
- Michelle C Callegan3 shared
- Angela Meier3 shared
- Victor Nizet3 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Victor Nizet$31,303,620
- Angela Meier$1,009,165
- Nisarg J. Shah$1,632,041
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoNanotechnologyBaseNanoparticleSurfacePharmaceutical PreparationsNanotherapeuticAntibioticsMembraneMouse ModelInfectionIn VitroPathogenResistanceEngineeringToxic EffectCellsSuccessNovel TherapeuticsDesignCell MembraneBacteriaInflammationProperty
Grant awards (23)
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia$991,226
R01 · FY2025 · AI
Intra-Articular Drug Delivery Modulating Immune Cells in Inflammatory Joint Disease$436,969
R01 · FY2025 · AR · contact PI
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia$1,009,268
R01 · FY2024 · AI
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia$1,027,000
R01 · FY2023 · AI
Membrane-cloaked nanoparticles as mucosal vaccines against giardiasis$197,500
R21 · FY2022 · AI
Membrane-cloaked nanoparticles as mucosal vaccines against giardiasis$237,000
R21 · FY2021 · AI
Nanoparticle decoys for treating infections with enterotoxin-producing pathogens$450,673
R33 · FY2020 · AI
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$359,138
R01 · FY2020 · CA · contact PI
Nanoparticle decoys for treating infections with enterotoxin-producing pathogens$450,673
R33 · FY2019 · AI
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$348,363
R01 · FY2019 · CA · contact PI
Nanoparticle decoys for treating infections with enterotoxin-producing pathogens$450,673
R33 · FY2018 · AI
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$359,138
R01 · FY2018 · CA · contact PI
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$359,138
R01 · FY2017 · CA · contact PI
Nanotherapeutics for Ocular Infections$357,722
R01 · FY2017 · EY
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$372,888
R01 · FY2016 · CA · contact PI
Nanotherapeutics for Ocular Infections$359,315
R01 · FY2016 · EY
Innate Antimicrobial Nanotherapeutics for the Treatment of H. pylori Infection$325,571
R01 · FY2016 · DK · contact PI
Nanoparticle decoys for treating infections with enterotoxin-producing pathogens$306,459
R21 · FY2016 · AI
Nanotherapeutics for Ocular Infections$372,766
R01 · FY2015 · EY
Innate Antimicrobial Nanotherapeutics for the Treatment of H. pylori Infection$326,621
R01 · FY2015 · DK · contact PI
Innate Antimicrobial Nanotherapeutics for the Treatment of H. pylori Infection$327,576
R01 · FY2014 · DK · contact PI
Innate Antimicrobial Nanotherapeutics for the Treatment of H. pylori Infection$316,949
R01 · FY2013 · DK · contact PI
Innate Antimicrobial Nanotherapeutics for the Treatment of H. pylori Infection$329,148
R01 · FY2012 · DK · contact PI